CGON CG Oncology, Inc. Common stock

Voya Investment Management LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 217.6% in the third quarter, bringing its total holdings to 47,986 shares valued at approximately $1.93 million. This comes as other institutional investors have also adjusted their positions, and despite recent insider selling, Wall Street analysts maintain a "Moderate Buy" rating for CG Oncology with an average price target of $60.58. The clinical-stage biopharmaceutical company focuses on novel antibody-based immunotherapies for solid tumor cancers.

CG Oncology (CGON) recently released positive topline data from its BOND-003 and CORE-004 trials for cretostimogene in non-muscle invasive bladder cancer (NMIBC), demonstrating encouraging efficacy and a consistent safety profile. Despite these strong results, the company's stock has fallen 8.7%, likely due to market debates on durability and competitive positioning. While the data strengthens CG Oncology's investment narrative for future Phase 3 readouts, the company remains largely pre-revenue and loss-making, with significant clinical, regulatory, and financing risks.

The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology, Inc. have launched an annual research fellowship to support early-career investigators in Non-Muscle Invasive Bladder Cancer (NMIBC). Two awards of up to $50,000 each are available for one-year basic, translational, or clinical research projects, with applications due by February 27, 2026. Awardees are expected to present their work at the SUO meeting at the AUA.

The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology have announced their second annual NMIBC Research Fellowship, aiming to support clinical cancer investigators focused on non-muscle invasive bladder cancer. Two recipients will each receive a $50,000 grant, with applications due by February 27, 2026. This initiative seeks to advance research and improve treatments for bladder cancer, with presentations of completed projects at the American Urological Association annual meeting.

CG Oncology, Inc. (NASDAQ:CGON) has received an average "Moderate Buy" rating from fifteen brokerages, with a consensus 12-month price target of $60.58. Despite this positive outlook and several recent price target raises, insiders have been net sellers, offloading approximately $1.89 million worth of shares. The company remains unprofitable, reflected in its current stock price of $40.94 and a negative EPS.

CG Oncology has announced the appointment of Arthur T. Rossi to its Board of Directors. Rossi brings over 30 years of experience in the biopharmaceutical industry, with a strong background in financial and operational leadership, which will be valuable as CG Oncology advances its clinical programs.